DeepMed Research

ZAI Lab (Shanghai) Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2014-01-06

Employees: -

Market Cap: -

Website: http://www.zailaboratory.com

Clinical Trials

A Study of ZL-1310 in Participants With Selected Solid Tumors

Phase 1

Not yet recruiting

Conditions: Solid Tumors

Interventions: Drug: ZL-1310

First Posted Date: 2025-03-20

Last Posted Date: 2025-04-20

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 86

Registration Number: NCT06885281

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: SCLC

Interventions: Drug: ZL-1310
Drug: Atezolizumab
Drug: Carboplatin

First Posted Date: 2023-12-21

Last Posted Date: 2025-01-10

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 85

Registration Number: NCT06179069

Locations: 🇺🇸
Zai Lab Site 2030, New Haven, Connecticut, United States
🇺🇸
Zai Lab Site 2029, Pittsburgh, Pennsylvania, United States
🇨🇳
Zai Lab Site 1004, Hefei, Anhui, China

and more 30 locations

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Phase 1

Completed

Conditions: Solid Malignancies

First Posted Date: 2023-05-19

Last Posted Date: 2023-11-27

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 19

Registration Number: NCT05866354

Locations: 🇨🇳
Jinan Central Hospital, Jinan, Shangdong, China

The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced or Metastatic Solid Tumor

Interventions: Drug: MRTX849

First Posted Date: 2022-03-03

Last Posted Date: 2023-02-27

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 22

Registration Number: NCT05263986

Locations: 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 5 locations

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Phase 1

Terminated

Conditions: Untreated Mucosal or Acral Lentiginous Melanoma
Unresectable, Recurrent or Metastatic Melanoma

Interventions: Drug: MGD013

First Posted Date: 2020-12-04

Last Posted Date: 2024-01-29

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 92

Registration Number: NCT04653038

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 10 locations

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor(GIST)

Interventions: Drug: Ripretinib
Drug: Sunitinib

First Posted Date: 2020-11-18

Last Posted Date: 2025-02-10

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 108

Registration Number: NCT04633122

Locations: 🇨🇳
The 4th Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳
The Cancer Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

and more 15 locations

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

Phase 1

Completed

Conditions: HER2 Positive Metastatic Breast Cancer

Interventions: Drug: Margetuximab Margetuximab-IV

First Posted Date: 2020-05-21

Last Posted Date: 2021-06-14

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT04398108

Locations: 🇨🇳
The fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The fifth medical center of the General Hospital of people's Liberation Army of China, Beijing, Beijing, China

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: ZL-2306(Niraparib）

First Posted Date: 2020-05-18

Last Posted Date: 2022-08-29

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 15

Registration Number: NCT04392102

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Sir Run Shaw Hospital, school of medicine, Zhejiang University, Guangzhou, Zhejiang, China
🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China

and more 4 locations

A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: DCC-2618

First Posted Date: 2020-02-25

Last Posted Date: 2025-03-03

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 39

Registration Number: NCT04282980

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
Chinese People's Liberation Army General Hospital, Beijing, Beijing, China

and more 6 locations

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Phase 2

Active, not recruiting

Conditions: Breast Cancer Metastatic

Interventions: Drug: Margetuximab
Drug: Trastuzumab
Drug: Chosen Chemotherapy (Capecitabine)
Drug: Chosen Chemotherapy (Vinorelbine )
Drug: Chosen Chemotherapy (Gemcitabine )

First Posted Date: 2020-02-10

Last Posted Date: 2023-08-22

Lead Sponsor: Zai Lab (Shanghai) Co., Ltd.

Target Recruit Count: 123

Registration Number: NCT04262804

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy